Mn Services Vermogensbeheer B.V. Has $7.50 Million Stake in Hologic, Inc. (HOLX)

Mn Services Vermogensbeheer B.V. grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 155,003 shares of the medical equipment provider’s stock after buying an additional 5,200 shares during the quarter. Mn Services Vermogensbeheer B.V. owned 0.05% of Hologic worth $7,502,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Oregon Public Employees Retirement Fund raised its position in Hologic by 3,960.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 1,192,649 shares during the period. Horan Capital Advisors LLC. bought a new stake in Hologic in the first quarter worth about $33,000. Lindbrook Capital LLC bought a new stake in Hologic in the fourth quarter worth about $36,000. Essex Savings Bank bought a new stake in Hologic in the fourth quarter worth about $37,000. Finally, First Interstate Bank bought a new stake in Hologic in the first quarter worth about $40,000. Hedge funds and other institutional investors own 97.84% of the company’s stock.

Several brokerages have commented on HOLX. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a research report on Tuesday, March 5th. TheStreet raised shares of Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 4th. BTIG Research reaffirmed a “buy” rating and issued a $52.00 price objective on shares of Hologic in a research report on Thursday, May 2nd. Finally, ValuEngine raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, February 15th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $45.41.

In other news, Director Sally Crawford sold 12,306 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $47.61, for a total value of $585,888.66. Following the sale, the director now owns 168,886 shares of the company’s stock, valued at $8,040,662.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Benjamin Jordan Cohn sold 6,830 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $46.70, for a total transaction of $318,961.00. Following the completion of the sale, the insider now directly owns 22,002 shares in the company, valued at approximately $1,027,493.40. The disclosure for this sale can be found here. In the last three months, insiders sold 23,378 shares of company stock worth $1,105,836. Insiders own 0.90% of the company’s stock.

NASDAQ HOLX opened at $44.91 on Thursday. Hologic, Inc. has a 12-month low of $37.47 and a 12-month high of $48.82. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.02 and a current ratio of 1.45. The company has a market capitalization of $11.96 billion, a PE ratio of 20.14, a price-to-earnings-growth ratio of 2.06 and a beta of 0.71.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The company had revenue of $818.40 million for the quarter, compared to analyst estimates of $806.99 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. Research analysts predict that Hologic, Inc. will post 2.42 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Mn Services Vermogensbeheer B.V. Has $7.50 Million Stake in Hologic, Inc. (HOLX)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2019/05/16/mn-services-vermogensbeheer-b-v-has-7-50-million-stake-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Trading Ex-Dividend Strategy

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply